N-(3-哌啶基)甲磺酰胺 | 944068-21-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-(3-哌啶基)甲磺酰胺
• 英文名称: N-(3-piperidyl)methanesulfonamide
• 英文别名: N-piperidin-3-ylmethanesulfonamide
• CAS: 944068-21-7
• 化学式: C₆H₁₄N₂O₂S
• 分子量: 178.255
• InChiKey: DHGIQFYIIZOGKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  66.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] SORDARIN DERIVATIVES FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS<br/>[FR] DÉRIVÉS DE SORDARINE POUR PRÉVENIR OU TRAITER DES MALADIES INFECTIEUSES CAUSÉES PAR DES MICRO-ORGANISMES PATHOGÈNES
  申请人：ASTELLAS PHARMA INC

  公开号：WO2009131246A1

  公开（公告）日：2009-10-29

  This invention relates to a new sordarin derivative or a pharmaceutically acceptable salt thereof, which has antimicrobial activities (especially, antifungal activities), to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases in a human being or an animal.

  这项发明涉及一种新的索达林衍生物或其药用可接受的盐，该衍生物具有抗菌活性（特别是抗真菌活性），其制备方法，包含该衍生物的药物组合物，以及用于预防或治疗人类或动物传染性疾病的方法。
• [EN] NOVEL HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE BCR-ABL INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES COMME INHIBITEURS DE LA TYROSINE KINASE BCR-ABL
  申请人：ASTAR BIOTECH LLC

  公开号：WO2017186148A1

  公开（公告）日：2017-11-02

  Disclosed is a compound of Formula (Ⅰ) or a pharmaceutically acceptable salt thereof, wherein the variables are described herein. Also disclosed is a process for the preparation of compounds, their pharmaceutical compositions comprising the same as an active ingredient, methods using said compositions in the treatment of various disorders, and use of the compounds in the manufacture of a medicament in inhibition of the enzymatic activities of ABL1, ABL2 and related chimeric proteins.

  揭示了一种式（Ⅰ）的化合物或其药学上可接受的盐，其中所述的变量在此处描述。还揭示了一种制备化合物的方法，其药用组合物包括作为活性成分的相同化合物，使用这些组合物治疗各种疾病的方法，以及利用这些化合物制造药物以抑制ABL1、ABL2和相关嵌合蛋白的酶活性。
• DERIVATIVES OF BETA-AMINO ACID AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS
  申请人：Sattigeri Jitendra A.

  公开号：US20090156465A1

  公开（公告）日：2009-06-18

  The present invention relates to β-amino acid derivatives as dipeptidyl peptidase-IV inhibitors and the processes for the synthesis of the same. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating diabetes, especially type 2 diabetes, as well as prediabetes, diabetic dyslipidemia, metabolic acidosis, ketosis, satiety disorders, and obesity. These inhibitors can also be used to treat conditions manifested by a variety of metabolic, neurological, anti-inflammatory, and autoimmune disorders like inflammatory disease, multiple sclerosis, rheumatoid arthritis; viral, cancer and gastrointestinal disorders. The compounds of this invention can also be used for treatment of infertility arising due to polycystic ovary syndrome.

  本发明涉及β-氨基酸衍生物作为二肽基肽酶-IV抑制剂及其合成过程。本发明还涉及含有本发明化合物的药物组合物，以及治疗糖尿病，特别是2型糖尿病，以及糖尿病前期，糖尿病脂质代谢紊乱，代谢性酸中毒，酮症，饱腹障碍和肥胖症的方法。这些抑制剂还可以用于治疗一系列代谢性，神经性，抗炎性和自身免疫性疾病的症状，如炎症性疾病，多发性硬化症，类风湿关节炎；病毒，癌症和胃肠疾病。本发明化合物还可用于治疗由多囊卵巢综合症引起的不孕症。
• Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors
  申请人：SOUTHERN RESEARCH INSTITUTE

  公开号：US11524010B2

  公开（公告）日：2022-12-13

  In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在一个方面，公开了抑制TXNIP表达和/或降低肝糖生成的化合物和组合物，以及识别、制造和使用这些化合物和组合物的方法。所公开的化合物和组合物可用于治疗与 TXNIP 升高和/或胰高血糖素水平升高相关的疾病，例如糖尿病及相关疾病。此外，还提供了治疗高脂血症或脂肪肝的方法，这些疾病可选地与 TXNIP 和/或胰高血糖素水平升高有关。本摘要旨在作为一种扫描工具，用于特定技术领域的搜索，并非对本发明的限制。
• SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF
  申请人：Advinus Therapeutics Limited

  公开号：EP2688890B1

  公开（公告）日：2017-08-30